Understanding Peripartum Cardiomyopathy

Annu Rev Med. 2018 Jan 29;69:165-176. doi: 10.1146/annurev-med-041316-090545. Epub 2017 Aug 16.

Abstract

Peripartum cardiomyopathy (PPCM) is the unexplained loss of maternal cardiac systolic function in the period surrounding parturition. PPCM affects women worldwide and is a leading cause of maternal mortality. The cause of PPCM has remained elusive until recently. We review here the epidemiology of PPCM, recent findings that strongly indicate hormonal and genetic contributions to the development of PPCM, and implications for the management of women with PPCM.

Keywords: African-American; peripartum cardiomyopathy; preeclampsia; prolactin; sFlt1.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Cardiomyopathies / epidemiology
  • Cardiomyopathies / genetics
  • Cardiomyopathies / physiopathology*
  • Cardiomyopathies / therapy
  • Connectin / genetics
  • Defibrillators
  • Female
  • Humans
  • Mutation
  • Peripartum Period
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / epidemiology
  • Pregnancy Complications, Cardiovascular / genetics
  • Pregnancy Complications, Cardiovascular / physiopathology*
  • Pregnancy Complications, Cardiovascular / therapy
  • Prolactin / metabolism*
  • Puerperal Disorders / epidemiology
  • Puerperal Disorders / genetics
  • Puerperal Disorders / physiopathology*
  • Puerperal Disorders / therapy
  • Vascular Endothelial Growth Factor Receptor-1 / metabolism*
  • Wearable Electronic Devices

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Connectin
  • TTN protein, human
  • Prolactin
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1